Literature DB >> 12125969

The combination of X-ray-mediated radiosurgery and gene-mediated immunoprophylaxis for advanced intracerebral gliosarcomas in rats.

H M Smilowitz1, J A Coderre, M M Nawrocky, W Tu, A Pinkerton, G H Jahng, N Gebbers, D N Slatkin.   

Abstract

Rats with advanced, imminently lethal, approximately 4 mm diameter, left-sided intracerebral 9L gliosarcoma (9LGS), a well characterized malignant tumor with some similarities to human high-grade astrocytomas, were used as a therapy model 14 days post-implantation of 10(4) cells. Such tumor-bearing rats die within two weeks (median, 6 days) thereafter if untreated. However, if these tumors are exposed on day 14 to 12-25 Gy of an electron-equilibrated 6 MV photon beam (radiosurgery), survival is extended about 5-6 fold to a median of 34 days, but long-term survival (> 1 year) is increased only to approximately 18%. Multiple subcutaneous inoculations of radiation-disabled 9LGS cells post-radiosurgery (immunoprophylaxis) extended lifespan and long-term (> 1 year) survival minimally (median, 37 days; 25%, respectively). In sharp contrast, radiosurgery followed by multiple subcutaneous inoculations of radiation-disabled 9LGS cells that had been transfected with granulocyte macrophage colony stimulating factor (GMCSF), a cytokine with demonstrated immune-enhancing properties (i.e. gene-mediated immunoprophylaxis, GMIMPR) increased long-term survival to approximately 67%. To our knowledge, these results are the first to show that the combination of photon radiosurgery and GMIMPR is effective for an advanced, imminently lethal brain tumor in a mammal. These data raise the possibility that GMIMPR following radiation therapy might prove effective for the treatment of some human malignant gliomas.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12125969     DOI: 10.1023/a:1015709406449

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  25 in total

Review 1.  Cytokine-secreting tumor cell vaccines.

Authors:  N Mach; G Dranoff
Journal:  Curr Opin Immunol       Date:  2000-10       Impact factor: 7.486

2.  Interleukin-12-based immunotherapy against rat 9L glioma.

Authors:  W C Jean; S R Spellman; M A Wallenfriedman; W A Hall; W C Low
Journal:  Neurosurgery       Date:  1998-04       Impact factor: 4.654

3.  Treatment of intracranial gliomas with bone marrow-derived dendritic cells pulsed with tumor antigens.

Authors:  L M Liau; K L Black; R M Prins; S N Sykes; P L DiPatre; T F Cloughesy; D P Becker; J M Bronstein
Journal:  J Neurosurg       Date:  1999-06       Impact factor: 5.115

4.  Cytokine gene therapy of gliomas: induction of reactive CD4+ T cells by interleukin-4-transfected 9L gliosarcoma is essential for protective immunity.

Authors:  K M Giezeman-Smits; H Okada; C S Brissette-Storkus; L A Villa; J Attanucci; M T Lotze; I F Pollack; M E Bozik; W H Chambers
Journal:  Cancer Res       Date:  2000-05-01       Impact factor: 12.701

5.  Granulocyte-macrophage colony-stimulating factor (GM-CSF) secreted by cDNA-transfected tumor cells induces a more potent antitumor response than exogenous GM-CSF.

Authors:  F S Shi; S Weber; J Gan; A L Rakhmilevich; D M Mahvi
Journal:  Cancer Gene Ther       Date:  1999 Jan-Feb       Impact factor: 5.987

Review 6.  Genetically modified tumor cell vaccines.

Authors:  F S Hodi; G Dranoff
Journal:  Surg Oncol Clin N Am       Date:  1998-07       Impact factor: 3.495

Review 7.  The radiation biology of boron neutron capture therapy.

Authors:  J A Coderre; G M Morris
Journal:  Radiat Res       Date:  1999-01       Impact factor: 2.841

8.  Neuropathology of ablation of rat gliosarcomas and contiguous brain tissues using a microplanar beam of synchrotron-wiggler-generated X rays.

Authors:  J A Laissue; G Geiser; P O Spanne; F A Dilmanian; J O Gebbers; M Geiser; X Y Wu; M S Makar; P L Micca; M M Nawrocky; D D Joel; D N Slatkin
Journal:  Int J Cancer       Date:  1998-11-23       Impact factor: 7.396

9.  Treatment of glioma by engineered interleukin 4-secreting cells.

Authors:  J S Yu; M X Wei; E A Chiocca; R L Martuza; R I Tepper
Journal:  Cancer Res       Date:  1993-07-01       Impact factor: 12.701

10.  Tumor-specific transplantation immunity to intracerebral challenge with cells from a methylnitrosourea- induced brain tumor.

Authors:  R H Denlinger; D A Axler; A Koestner; L Liss
Journal:  J Med       Date:  1975
View more
  2 in total

1.  Multi-focal gliosarcoma: a case report and review of the literature.

Authors:  E E Pakos; A C Goussia; V P Zina; E J Pitouli; P G Tsekeris
Journal:  J Neurooncol       Date:  2005-09       Impact factor: 4.130

2.  Synergy of gene-mediated immunoprophylaxis and microbeam radiation therapy for advanced intracerebral rat 9L gliosarcomas.

Authors:  H M Smilowitz; H Blattmann; E Bräuer-Krisch; A Bravin; M Di Michiel; J-O Gebbers; A L Hanson; N Lyubimova; D N Slatkin; J Stepanek; J A Laissue
Journal:  J Neurooncol       Date:  2006-04-06       Impact factor: 4.130

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.